ArticleInfection
A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7.
Article in Infection. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 42 citations in OpenAlex.
- Selective IgG binding to the LPS glycolipid core found in bovine colostrum, or milk, duringInnate immunity · 2024Article
- Bovine colostrum and its potential contributions for treatment and prevention of COVID-19.Frontiers in immunology · 2023Review
- Antibodies against spike protein of SARS-CoV-2 variants in bovine whey IgG enriched fraction.International dairy journal · 2022Article
- Presence of antibodies against SARS-CoV-2 spike protein in bovine whey IgG enriched fraction.International dairy journal · 2021Article
- Immunoglobulin G from bovine milk primes intestinal epithelial cells for increased colonization of bifidobacteria.AMB Express · 2020Article
- KMP01D Demonstrates Beneficial Anti-inflammatory Effects on Immune Cells: AnFrontiers in immunology · 2020Article
- Enriched bovine IgG fraction prevents infections with EnterohaemorrhagicFood science & nutrition · 2019Article
- Effects of Bovine Immunoglobulins on Immune Function, Allergy, and Infection.Frontiers in nutrition · 2018Review
- Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs.Comparative medicine · 2009Article
- Bovine colostrum contains immunoglobulin G antibodies against intimin, EspA, and EspB and inhibits hemolytic activity mediated by the type three secretion system of attaching and effacing Escherichia coli.Clinical and vaccine immunology : CVI · 2008Article
- Bovine colostrum in oral treatment of enterogenic endotoxaemia in rats.Critical care (London, England) · 2002Article
- Antibacterial agents and release of periplasmic pertussis toxin from Bordetella pertussis.Antimicrobial agents and chemotherapy · 2000Article
- Passive immunity against human pathogens using bovine antibodies.Clinical and experimental immunology · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterohemorrhagic Escherichia coli (EHEC) causes a variety of clinical conditions, the most important being hemorrhagic colitis and hemolytic uremic syndrome. A curative therapy of EHEC diseases is not yet feasible. This study investigates the antibody reactivity of Lactobin, a standardized immunoglobulin (Ig) preparation, obtained from the colostra of non-immunized cows. Three different batches of Lactobin exhibited equally high titers of specific antibodies against Shiga-like toxins (SLTs, verocytotoxins) and EHEC hemolysin (EHEC-Hly) produced by E. coli O157. In addition, Lactobin blocked the cytotoxic effect of SLT-I and SLT-II on Vero cell monolayers and inhibited the cytolytic effects of EHEC-Hly on human erythrocytes. Since Lactobin contains high levels of antibodies and neutralizing activity against important virulence factors of EHEC O157, this drug has potential use in the treatment of diarrhea and the prevention of EHEC-associated hemolytic uremic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.